ClinicalTrials.gg
WithdrawnNCT06848192Updated Sep 29, 2026

The Parkinson's Disease Case-Control Study

An observational study in Parkinson Disease, sponsored by Westlake University. Withdrawn at 1 site in China. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Westlake University · Observational

How we know

Why this study was withdrawn
Due to challenges in obtaining faecal samples from patients with Parkinson's disease, a population frequently affected by constipation.
Updated Sep 29, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
0
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
67th of 68
0 · median 215
Started
2025
with 32 others
Observational
68 of 279
34 open now
Registered
200th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 67th largest by enrollment of the 68 observational ones that give a count, is one of 33 that started in 2025, is one of 68 observational ones, and was the 200th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

The Parkinson's Disease Case-Control Study is a study of healthy volunteers and patients with Parkinson's disease aged 50-75 years living in Hangzhou, China. This study aims to systematically investigate the differences in intestinal fungi between patients and healthy volunteers, find the key strains, and explore the molecular mechanism of Parkinson's disease with multi-omics data. Another aim of this study is to explore the association between intestinal fungi and brain structure and function from the perspective of the gut-brain axis by combining brain image data.

Read the detailed description

Parkinson's disease is the second most common neurodegenerative disease of the central nervous system. Recent studies have shown that gut microorganisms, through their metabolites, can directly and indirectly affect brain function and neurodegenerative processes through the immune system, endocrine system, and nervous system, thus affecting the progress of Parkinson's disease. Gut fungi, as an important component of gut microorganisms, are rarely studied in Parkinson's disease. To systematically explore the differences in intestinal fungi between patients with Parkinson's disease and healthy volunteers, this project is expected to recruit 20 healthy volunteers and 20 Parkinson's disease patients respectively. The Parkinson's Disease Case-Control Study design incorporates collecting demographic information and clinical characteristics of Parkinson's disease patients and healthy volunteers, as well as biological samples (blood, urine, stool) and brain magnetic resonance imaging (MRI) of the subjects.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All the participants should be residents living in Hangzhou, China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(For PD patients)

  1. Men or women aged 50 to 75 years.
  2. Clinical diagnosis of Parkinson's disease (based on MDS Parkinson's disease diagnostic criteria)
  3. The patient must have at least two of the following symptoms: static tremor, bradykinesia, stiffness (which must include at least static tremor or bradykinesia); Or have asymmetrical resting tremors or asymmetrical bradykinesia.
  4. Able to provide .

(For healthy volunteers)

  1. Age (±2 years) and sex-matched healthy control individuals for each Parkinson's disease patient.
  2. Able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

(For PD patients)

  1. Atypical or secondary parkinsonism due to medications (e.g., metoclopramide, flunarizine, antipsychotics) or metabolic diseases (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).
  2. The presence of clinically diagnosed dementia as determined by the investigator.
  3. Previous MRI scans showed neurological disorders (as judged by the investigator).
  4. Serious illness (e.g., heart failure or ).
  5. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction
  6. Inflammatory gastrointestinal diseases.
  7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).
  8. Blood or disease, or use of in the past 3 months.
  9. Antibiotics have been used within 3 months prior to sample collection.
  10. Chronic constipation.

(For healthy volunteers)

  1. Have a first-degree relative with Parkinson's disease (e.g. biological parent, sibling, or child).
  2. Current or past clinically significant neurological disorders (as judged by the investigator).
  3. Previous MRI scans showed clinically significant neurological disorders (as judged by the investigator).
  4. Use of the following drugs in the 6 months prior to the screening visit: dopamine blockers (antipsychotics), metoclopramide, and riserpine.
  5. Inflammatory gastrointestinal diseases.
  6. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction
  7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).
  8. Blood or autoimmune disease, or use of immunosuppressants in the past 3 months.
  9. Antibiotics have been used within 3 months prior to sample collection.
  10. Chronic constipation.
  11. Participating in other clinical trials
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Gut microbiome profiling

    The microbiome profile is analyzed based on stool samples.

    Time frame: At enrollment

Secondary outcomes

  1. Fecal and serum metabolomics profiling

    Metabolomics profiles are analyzed based on blood samples and stool samples.

    Time frame: At enrollment

  2. Blood and urine proteomics profiling

    Proteomics profiles are analyzed based on blood samples and urine samples.

    Time frame: At enrollment

  3. Brain imaging features

    MRI scans are used to extract brain imaging features.

    Time frame: At enrollment

07

Study locations

1 site
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Dec 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 26, 2025
StartActual
Mar 5, 2025
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Due to challenges in obtaining faecal samples from patients with Parkinson's disease, a population frequently affected by constipation.
changed Sep 29, 2026
Enrollment
40 (estimated)→0 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Withdrawn
    Why stopped Due to challenges in obtaining faecal samples from patients with Parkinson's disease, a population frequently affected by constipation.
    Enrollment 40 (estimated)→0 (actual)
    + 7 other changes: index terms, verification date, date precision, oversight details, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06848192
Lead sponsor
Westlake University
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Mar 5, 2025
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion